Just saw BridgeBio dropped some pretty significant Phase 3 data on their oral achondroplasia treatment - infigratinib. This is actually worth paying attention to if you follow biotech.

So here's the headline: they hit their primary endpoint hard. The drug showed a +1.74 cm/year improvement in annualized height velocity compared to placebo (p<0.0001). But honestly, the more interesting part is something they haven't really cracked before - body proportionality improvements in kids under 8. That's the first time any therapy has shown statistically significant results on this metric in a randomized trial. That matters because achondroplasia isn't just about height; it's about how your body develops proportionally, which impacts mobility and function long-term.

The safety profile looks clean too. No discontinuations, no serious adverse events tied to the drug. They had 3 cases of hyperphosphatemia (4% of participants), all mild and transient - nothing that required dose adjustments. No retinal or corneal issues either, which is important when you're inhibiting FGFR3.

What's interesting from a market perspective: they're planning NDA and MAA submissions in the second half of 2026. This is one of the few therapies with FDA Breakthrough Designation for achondroplasia. They're also accelerating development in hypochondroplasia - including mild hypochondroplasia cases - which opens up a potentially larger patient population. The Phase 3 PALO ALTO trial for hypochondroplasia is already enrolling.

The practical angle here is that this is an oral medication, not an injection. For families managing these conditions long-term, that's a meaningful difference in quality of life. The Little People of America rep even called out body proportionality as something families specifically wanted to see addressed.

If the regulatory path stays on track, you could see this approved within 18 months. Worth keeping on your radar if you're watching rare disease therapeutics or biotech catalysts.